It is critical to identify the cell of origin of cancer and the genes/proteins/transcriptional/epigenetic factors of that cell.
Introduction
There are several prepositions that cancers arise from founder cells that are differentiated or an early progenitor cell or possibly the primary stem cell which undergoes aberrant reprogramming and result in cancer. Stem cells live the longest in the body and exhibit heterogeneity, self-renewal and slow cycling. Since these persist for the lifetime of an individual, these are more likely to accumulate mutations. Cancer cells with properties of stem cells are called cancer stem cells (CSCs) which have tumourigenic and metastatic capacity. Since CSCs are thought to give rise to tumours, understanding their properties, components and physiological roles are crucial. [1] The new hierarchical model of CSC has been introduced [ Figure 1 ] as opposed to clonal evolution of cancer. [2] The ability to isolate these stem/progenitor cells by flow cytometry or magnetic beads and expanding them in culture flask gives us a powerful resource for highthroughput screens that could yield potentially novel therapies for cancer treatment.
There is a mechanistic link between cancer and reprogramming of cell and involves a gain or loss of only a certain number of genes/proteins/transcriptional/ epigenetic factors that are dominant enough to induce reprogramming. This is supported by studies that suggested a single transcription factor could be all that is required to induce the reprogramming as long as it is the right factor for the right cell type. [3, 4] The four transcription factors, OCT3/4 (octamer-binding transcription factor 3 and 4), SOX-2 (sex-determining region Y), c-MYC and KLF4 oncogene (a gene which in certain circumstances can transform a cell into a tumour cell) shown by Takahashi [5] in their breakthrough work has also been reported to play oncogenic roles.
CSC Evidence in Head and Neck Cancer
Cancers of the head and neck squamous cell carcinomas (HNSCC) (six major sites: The oral cavity, pharynx [nasopharynx, oropharynx and hypopharynx], larynx, paranasal sinuses, salivary glands and thyroid gland) may arise from any of the lining membranes of the upper aerodigestive tract.
Existence of CSCs has been reported both in human HN tumours from patients and cell lines derived from primary tumours. After the first report on breast CSCs (CD44 + CD24 − ) in 2003, growing evidence supported the concept that a subset of undifferentiated cells, with the ability to self-renewal, in several solid tumours such as brain (CD133 + ), colon (CD133 + ), prostate (CD44 + ), skin (CD20 + ) and pancreas (CD44 + CD24 + ) is generated, maintained and regrow into the bulk tumour population. [6] [7] [8] [9] [10] [11] [12] [13] The cluster of differentiation (CD) is a protocol used for the identification and investigation of cell surface molecules present on cells. Prince et al. contributed the first report for the existence of CSCs in HN cancer with the use of CD44 as a marker for CSCs from primary tumours. [14] This study also performed the gold standard CSC test, the limiting dilution transplantation assay (LDA), in immune-compromised mice that determine the minimum number (5000) of CD44 + cells for tumour formation while CD44cells failed to form tumours in the mice. Another study in the same year demonstrated that clonogenicity is restricted to a subpopulation of total cells within HNSCC each of which can generate populations with full range of heterogeneity present in parent cell line reflecting a stem cell pattern. [15] They found three different colonies, namely holoclones (compact, round and least differentiated), meroclones (scattered cells) and paraclones (more scattered cells having the highest degree of differentiation) from parent cell lines. Only holoclones resembling tumour contained CSCs while other two with more scattered cells were less likely to contain CSC [ Figure 2 ]. Several observations made in these studies on HNSCC cell lines indicated that criteria sufficient to indicate persistence of stem cell pattern i.e., self-renewal, amplifying hierarchy and ability of differentiation are met.
Head and neck CSCs (HNCSCs) live in nearby vicinity of accompanying blood vessels known as the perivascular niche which provides a conducive environment for them to flourish and multiply. [17, 18] Mutations attained overtime, in normal stem cells, empowers these cells for self-renewing property within an alternative niche which, in turn, becomes a proliferative hub for other mutant stem cells, hence, converting them to CSC. Alison et al. reported that self-renewal pathways (WNT, Hedgehog and Notch) impart vastly differentiating property to CSCs and make them unique for tumour progression. [19] A study reported that enriched CD133 + CSCs from four OSCC cell lines, PCI-4A, PCI-8, PCI-9A and PCI-13, showed reduced sensitivity to paclitaxel through ATP-binding cassette (ABC) drug transporters. [20] 
Proteomics of Head and Neck Cancer
From a highly invasive oral cancer cell line UM1, non-adherent CSC-like cells (SOX2 high OCT4 high SOX9 high CD44 high HIF-1α low PGK-1 low ) and adherent non-CSC UM1 cells were isolated. A lowly invasive UM2 oral cancer cell line was used as a control. Using . The CSC (in red) undergoes a division to give rise to a differentiated daughter cell (blue) and another CSC (red, self-renewal depicted by red arrow). The CSC by virtue of its infinite proliferative potential will continue to divide as above (dotted arrow). The differentiated cell may undergo a few divisions before terminal differentiation or senescence or cell death as the case may be. The CSC may undergo clonal evolution and acquire even greater tumourigenicity and/or chemoresistance and/or radioresistance (brown). Alternatively, a differentiated cell may dedifferentiate and acquire tumourigenicity (black arrow) and be converted to a CSC. (b) Clonal evolution model. Normal cells (blue) acquire mutations stochastically (yellow) and over successive divisions, and due to accrual of several mutations, these cells become transformed (red) and/or acquire chemo-and/or radio-resistance and can divide indefinitely (dotted arrow). Figure  from Mitra et al., 2011 [2] b a quantitative tandem mass tagging, a significant proteomic alteration between CSC-like and non-CSC UM1 cells was observed. In particular, transcriptional coactivator CBP (CREB-binding protein) and phosphorylated CREB-1 (cyclic AMP response element-binding protein 1) were significantly upregulated in CSC-like UM1 cells versus non-CSC UM1 cells, suggesting that the CREB pathway is activated in the CSC-like cells. [21] Although there is ample evidence for the existence of CSCs, yet their isolation faces challenges because a definite marker has not been identified. Several cell surface receptors and intracellular proteins have been reported to be differently expressed between stem cells and differentiated mature cells. In HN cancer tissues, little progress has been made to mark CSCs. The widely accepted markers [ Table 1 ] are also expressed by other basal layer cells which only allow for enrichment of CSCs instead of the isolation of pure cell population. The ambiguity of CSC markers is persisting despite large body of literature and information. [22] The suggested cell surface marker of CSCs in OSCC is hyaluronan receptor CD44; [14] however, there are contradictory reports on utility of CD44 with various isoforms as a marker for HNCSCs [23] and its role was questioned by a study in which both CD44 + and CD44 − cells from squamospheres regenerated spheres from single cell suspension. [24] The expression of CD44 variants was associated with regional metastasis (CD44v3), perineural invasion (CD44v6) and radiation failure (CD44v10). [25] Cells expressing high CD29 and CD44 which can be used as markers to enrich CSCs in human SCC exhibiting molecular characteristics of EMT (a mechanism imparting stem-like properties to differentiated cells) suggest that CSC-associated pathways were involved in EMT. The first report of lung metastasis of HN cancer stem-like cells describing transcription factor SNAIL1 (zinc finger protein), oncogene BMI-1 (polycomb complex protein) and oxidation enzyme ALDH 
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(aldehyde dehydrogenase) as worst prognostic factors, strengthened the link between EMT and stemness in HN cancer. [26] Oral cancer cell line proteome was studied by MALDI-TOF MS/MS and IPA analysis predicted that at least 18 proteins including cell cycle regulator CLIC1 (chloride intracellular channel protein 1) and antigen processor proteasome activator complex subunit. [30] Two-dimensional electrophoresis and peptide mass fingerprinting detection of enolase-1 in the whole saliva were shown to be significantly higher for OSCC patients than for healthy individuals. [31] A low-molecular-weight candidate thioredoxin was detected by LC-MALDI-MSMS in oral fluids from OSCC patients and matched control patients, and the average level of thioredoxin in cancer samples was found to be about 3 times higher than that in normal samples (P < 0.01). [32] In recent study, a statistically significant higher abundance demonstrated that complement factor b, C3 (complement component 3), glycoprotein C4B (C4-binding protein), serine protease inhibitor SERPINA1 (alpha-1-antitrypsin) and signal transduction glycoprotein leucine-rich-alpha-2 glycoprotein are associated with the risk of developing OSCC. [33] A total of 26 proteins representing 12 unique gene products were identified hypopharyngeal squamous cell carcinoma by 2D-DIGE and MALDI-TOF/TOF MS. The upregulated proteins were AHSG (alpha-2-HSglycoprotein), complement C4-B, haemoglobin-binding liver protein Hp (haptoglobin), marker of inflammation C-reactive protein and copper-binding enzyme CP (ceruloplasmin), whereas the downregulated proteins were plasma protein ALB (serum albumin), component 
Current Treatment Modalities in Head and Neck Cancer and Protein-specific Drugs in Trial
This is imperative to switch from current non-specific treatments to personalised medicine. Chemoresistance due to the heterogeneous group of tumour cells is wellreported impediment for failure of different therapeutic strategies. The challenges become multifold when disease spreads from its primary site. Even after the recent advancements in therapies for HN cancers, longterm survival rate is still poor. Since decades platinumbased agents (cisplatin) are being used as the first-line chemotherapeutic drugs for HN cancers, but their exact mechanism of action is not known. A p16-mediated cell cycle arrest with the use of cisplatin [ Table 2 ] was found to cause downregulation of tumour suppressor genes and suppression of p16 has been linked to cisplatin resistance in HN cancer. [34] An iTRAQ-based MALDI-MS proteomics study on four human HNSCC cell lines: Cisplatin-sensitive UM-SCC-23, UM-SCC-23-CDDPR with acquired cisplatin resistance, naturally cisplatinresistant UM-SCC-81B and UM-SCC-23/WR with acquired 5-fluorouracil resistance proposed α-Enolase as a true cisplatin chemoresistance factor of 13 proteins which were found to be associated with multidrug resistance. [35] Bortezomib is the first therapeutic FDA approved proteosome inhibitor treating relapsed multiple myeloma and mantle cell lymphoma. In HN cancers, its solitary role has not been quite promising however, combining bortezomib with TRAIL (tumor necrosis factor related apoptosis inducing ligand) receptor agonists produced a synergistic cytotoxic effect in TRAIL-resistant HPVpositive cells [ Table 2 ]. [36] A relatively new solid tumour treatment modality ALA-PDT (5-aminolevulinic acid-mediated photodynamic therapy) has been reported to reduce ALDH1 activity, CD44 positivity (widely accepted CSC markers), self-renewal and invasion of CSC in HN cancers resulting in enhanced chemosensitivity and apoptotic ability through NF-kB/JNK signalling and decrease migration capacity of oral cancer cells by downregulation of FAK (focal adhesion kinase) and ERK (extracellular signal-regulated kinase). [37] One compound, salinomycin, reduces the proportion of CSCs by >100-fold relative to paclitaxel, a commonly used cancer chemotherapeutic drug. [38] The combination of cetuximab and the hedgehog inhibitor IPI-926, the proliferation inhibitors, is more active than either single agent in patient-derived xenograft models of HNSCC. [39] 
Conclusions
We have presented an update in the area of head and neck cancer research highlighting a CSC model, identification of bona fide CSC marker is paramount.
The high-throughput techniques in the field of proteomics can play a powerful role in achieving this goal which might change the course of medicine. A better understanding of cycling dynamics at molecular level within hyper-and hypo-proliferative cell populations after radio-and chemo-therapy is needed to better treat cancer. Thus, regardless of, whether the resistance is primary or acquired, digging into the molecular mechanisms involved and discovering, the definitive therapies targeting CSCs have undoubtedly become a pivotal issue in the treatment of human cancers and so far extraordinary efforts have been put into, to describe some incredible chemotherapeutic agents that selectively target CSCs by aiming the various pathways involved in regulation of these cells.
Other salient mechanisms which can invalidate the therapeutic modalities include decreased intracellular drug accumulation, drug inactivation, perturbations in signal transduction pathways and apoptosis-/autophagyrelated chemoresistance.
